Страна: Канада
Език: английски
Източник: Health Canada
VALPROIC ACID (SODIUM VALPROATE)
APOTEX INC
N03AG01
VALPROIC ACID
250MG
SOLUTION
VALPROIC ACID (SODIUM VALPROATE) 250MG
ORAL
100
Prescription
MISCELLANEOUS ANTICONVULSANTS
Active ingredient group (AIG) number: 0112996002; AHFS:
APPROVED
2020-11-20
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr VALPROIC ACID Valproic Acid Capsules Capsules, 250 mg, Oral USP Pr VALPROIC ACID ORAL SOLUTION Valproic Acid Oral Solution Oral solution, 250 mg / 5 mL valproic acid (as sodium valproate), Oral USP Antiepileptic APOTEX INC. 150 Signet Drive Toronto, Ontario M9L 1T9 Date of Initial Authorization: November 20, 2020 Date of Revision: February 7, 2023 Submission Control Number: 267284 RECENT MAJOR LABEL CHANGES 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment 02/2023 7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic: Serious or Fatal Hepatotoxicity 02/2023 7 WARNINGS AND PRECAUTIONS, Psychiatric: Behavioural Disorders 02/2023 7 WARNINGS AND PRECAUTIONS, Reproductive Health: Female and Male Potential 02/2023 7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women, Pregnancy Exposure Risk related to Valproate 02/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES............................................................................................. 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS.................................................................................................................... 4 1.1 Pediatrics................................................................................................................. 4 1.2 Geriatrics ................................................................................................................. 4 2 CONTRAINDICATIONS ...................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX.................................................................. 5 4 DOSAGE AND ADMINISTRATION ........... Прочетете целия документ